Showing results (71-80 of 75) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Cancer Research|November 13, 2003
Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapyJean S Beebe, Jitesh P Jani, Elisabeth Knauth, et al.Cancer Research|March 15, 2008
Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271Walter Gregory Roberts, Ethan Ung, Pamela Whalen, et al.Cancer Research|February 12, 2005
Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451W Gregory Roberts, Pamela M Whalen, Erik Soderstrom, et al.Proceedings of the National Academy of Sciences of the United States of America|June 1, 2007
Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosisLeonard Buckbinder, David T Crawford, Hong Qi, et al.Bioorganic & Medicinal Chemistry Letters|October 28, 2008
Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formationDaniel P Walker, F Christopher Bi, Amit S Kalgutkar, et al.Pageof 8